urative-intent surgical resection remains the standard of care for all localized cholangiocarcinomas, and liver transplant for a subset of patients with unresectable, hilar cholangiocarcinoma.Unfortunately, most patients with cholangiocarcinoma present with unresectable or advanced-stage disease.In this case, locoregional and systemic chemotherapy is the primary treatment modality.Fortunately, however, in recent years, genomic, transcriptomic, and proteomic analyses have elucidated the molecular characteristics of cholangiocarcinoma and have led to an explosion in early-phase targeted therapy and immunotherapy trials focusing on each cholangiocarcinoma subtype.In this article, we highlight the emerging targeted and immunotherapies in cholangiocarcinoma.Specifically, in this article we discuss clinical trial results with IDH inhibitors, FGFR inhibitors, BRAF inhibitors, anti-HER2 directed therapies, and immune checkpoint inhibitors that have demonstrated favorable safety profiles and clinical responses in patients with disease that is refractory or intolerant to chemotherapy.We discuss the implications of these results and ongoing studies with the potential to change the standard of care for these patients in the near future.